# Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT

Study · id `cardio:ct-nct05124353` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05124353](<https://clinicaltrials.gov/study/NCT05124353>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05124353

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05124353. Randomized; no masking; primary purpose treatment. Start 2021-04-27 (actual); primary completion 2023-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05124353, source copy `cardio:ctgov-nct05124353-2021-11-17`, retrieved 2026-10-26)
- Started: 2021-04-27 (actual) (ClinicalTrials.gov record NCT05124353, source copy `cardio:ctgov-nct05124353-2021-11-17`, retrieved 2026-10-26)
- Primary completion: 2023-04-01 (anticipated) (ClinicalTrials.gov record NCT05124353, source copy `cardio:ctgov-nct05124353-2021-11-17`, retrieved 2026-10-26)
- Completion: 2023-04-01 (anticipated) (ClinicalTrials.gov record NCT05124353, source copy `cardio:ctgov-nct05124353-2021-11-17`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT05124353, source copy `cardio:ctgov-nct05124353-2021-11-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05124353-2021-11-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT
- Condition: Stroke, Acute, Ischemic
- Intervention (Drug): Cerebrolysin
- Lead sponsor: Pomeranian Medical University Szczecin
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Pomeranian Medical University Szczecin (`cardio:org-pomeranian-medical-university-szczecin`)

## Provenance

Content hash: a3d24420ac0b87a9937e9ee52124d96ec4c9051ade3758a590ab1f08f19d8dc7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
